The expression of secretory group IIA phospholipase A2 (sPLA2-IIA) has been shown to be elevated in various inflammatory diseases, and lipopolysaccharide (LPS) up-regulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Zingerone (ZGR), a phenolic alkanone isolated from ginger, has been reported to have various pharmacological activities. Here, we examined the effects of ZRG on the expression and activity of sPLA2-IIA in LPS-activated HUVECs and in mouse models of endotoxemia and sepsis. Treatment of cells or mice with ZRG inhibited LPS-induced expression and activity of sPLA2-IIA. In addition, ZRG suppressed LPS-mediated activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. These results suggest that ZRG inhibits LPS-mediated activation of sPLA2-IIA expression by suppressing cPLA2 and ERK 1/2.
GoldblumS.E., BrannT.W., DingX., PuginJ., TobiasP.S. (1994) Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. Journal of Clinical Investigation, 93, 692–702.
4.
BalukP., YaoL.C., FengJ., RomanoT., JungS.S., SchreiterJ.L., YanL., ShealyD.J., McDonaldD.M. (2009) TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. Journal of Clinical Investigation, 119, 2954–2964.
SixD.A., DennisE.A. (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochimica et Biophysica Acta, 1488, 1–19.
7.
VadasP., PruzanskiW. (1986) Role of secretory phospholipases A2 in the pathobiology of disease. Laboratory Investigation, 55, 391–404.
8.
PruzanskiW., VadasP. (1991) Phospholipase A2–a mediator between proximal and distal effectors of inflammation. Immunology Today, 12, 143–146.
9.
WaydhasC., Nast-KolbD., DuswaldK.H., LehnertP., SchweibererL. (1989) Prognostic value of serum phospholipase A in the multitraumatized patient. Klinische Wochenschrift, 67, 203–206.
10.
PruzanskiW., VadasP., StefanskiE., UrowitzM.B. (1985) Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. Journal of Rheumatology, 12, 211–216.
11.
VadasP., BrowningJ., EdelsonJ., PruzanskiW. (1993) Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. Journal of Lipid Mediators, 8, 1–30.
12.
TanakaK., KatoT., MatsumotoK., YoshidaT. (1993) Anti-inflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation, 17, 107–119.
13.
MurakamiM., NakataniY., AtsumiG., InoueK., KudoI. (1997) Regulatory functions of phospholipase A2. Critical Reviews in Immunology, 17, 225–283.
14.
Alaoui-El-AzherM., WuY., HavetN., IsraelA., LilienbaumA., TouquiL. (2002) Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPLA(2)-IIA expression in alveolar macrophages through NF-kappaB and PPAR-gamma-dependent pathways. Molecular Pharmacology, 61, 786–794.
15.
KuwataH., FujimotoC., YodaE., ShimbaraS., NakataniY., HaraS., MurakamiM., KudoI. (2007) A novel role of group VIB calcium-independent phospholipase A2 (iPLA2gamma) in the inducible expression of group IIA secretory PLA2 in rat fibroblastic cells. Journal of Biological Chemistry, 282, 20124–20132.
16.
FlynnJ.T., HoffH.3rd. (1995) Lipopolysaccharide induces time-dependent increases in prostaglandin H synthase-2 and cytosolic phospholipase A2 mRNA in cultured human microvessel-derived endothelial cells. Shock, 4, 433–440.
17.
OkaS., AritaH. (1991) Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. Journal of Biological Chemistry, 266, 9956–9960.
18.
CarassoR.L., VardiJ., RabayJ.M., ZorU., StreiflerM. (1977) Measurement of prostaglandin E2 in cerebrospinal fluid in patients suffering from stroke. Journal of Neurology, Neurosurgery, & Psychiatry, 40, 967–969.
19.
GaoW., SchmidtkoA., WobstI., LuR., AngioniC., GeisslingerG. (2009) Prostaglandin D2 produced by hematopoietic prostaglandin D synthase contributes to LPS-induced fever. Journal Of Physiology And Pharmacology, 60, 145–150.
20.
PriorR.L., CaoG. (1999) Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Proceedings of the Society for Experimental Biology and Medicine, 220, 255–261.
21.
WarrenC.P. (1999) Antioxidant effects of herbs. Lancet, 353, 676.
22.
ParkK.K., ChunK.S., LeeJ.M., LeeS.S., SurhY.J. (1998) Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Letters, 129, 139–144.
23.
SiesH., MasumotoH. (1997) Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Advances in Pharmacology, 38, 229–246.
RaoB.N., ArchanaP.R., AithalB.K., RaoB.S. (2011) Protective effect of zingerone, a dietary compound against radiation induced genetic damage and apoptosis in human lymphocytes. European Journal of Pharmacology, 657, 59–66.
26.
HemalathaK.L., PrinceP.S. (2015) Preventive effects of zingerone on altered lipid peroxides and nonenzymatic antioxidants in the circulation of isoproterenol-induced myocardial infarcted rats. Journal of Biochemical and Molecular Toxicology, 29, 63–69.
27.
BanjiD., BanjiO.J., PavaniB., Kranthi KumarC., AnnamalaiA.R. (2014) Zingerone regulates intestinal transit, attenuates behavioral and oxidative perturbations in irritable bowel disorder in rats. Phytomedicine, 21, 423–429.
28.
BurasJ.A., HolzmannB., SitkovskyM. (2005) Animal models of sepsis: setting the stage. Nature Reviews Drug Discovery, 4, 854–865.
29.
DiehlK.H., HullR., MortonD., PfisterR., RabemampianinaY., SmithD., VidalJ.M., van de VorstenboschC. (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology, 21, 15–23.
30.
BonventreJ.V., HuangZ., TaheriM.R., O'LearyE., LiE., MoskowitzM.A., SapirsteinA. (1997) Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature, 390, 622–625.
31.
TianW., WijewickramaG.T., KimJ.H., DasS., TunM.P., GokhaleN., JungJ.W., KimK.P., ChoW. (2008) Mechanism of regulation of group IVA phospholipase A2 activity by Ser727 phosphorylation. Journal of Biological Chemistry, 283, 3960–3971.
32.
MenschikowskiM., HagelgansA., HempelU., LattkeP., IsmailovI., SiegertG. (2008) On interaction of activated protein C with human aortic smooth muscle cells attenuating the secretory group IIA phospholipase A2 expression. Thrombosis Research, 122, 69–76.
33.
MenschikowskiM., HagelgansA., SiegertG. (2006) Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?Prostaglandins & Other Lipid Mediators, 79, 1–33.
34.
NakanoT., OharaO., TeraokaH., AritaH. (1990) Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. Journal of Biological Chemistry, 265, 12745–12748.
35.
CrowlR.M., StollerT.J., ConroyR.R., StonerC.R. (1991) Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry, 266, 2647–2651.
36.
BradleyJ.D., DmitrienkoA.A., KivitzA.J., GluckO.S., WeaverA.L., WiesenhutterC., MyersS.L., SidesG.D. (2005) A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. Journal of Rheumatology, 32, 417–423.
37.
ZeiherB.G., SteingrubJ., LaterreP.F., DmitrienkoA., FukiishiY., AbrahamE. (2005) LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Critical Care Medicine, 33, 1741–1748.
38.
GrassD.S., FelknerR.H., ChiangM.Y., WallaceR.E., NevalainenT.J., BennettC.F., SwansonM.E. (1996) Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. Journal of Clinical Investigation, 97, 2233–2241.
39.
BeckG., YardB.A., SchulteJ., HaakM., van AckernK., van der WoudeF.J., KaszkinM. (2003) Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium. Biochemical and Biophysical Research Communications, 300, 731–737.
40.
KuS.K., YoonE.K., LeeH.G., HanM.S., LeeT., BaeJ.S. (2015) Inhibitory effects of lysozyme on endothelial protein C receptor shedding in vitro and in vivo. BMB Reports, 48, 624–629.
41.
YoonE.K., KuS.K., LeeW., KwakS., KangH., JungB., BaeJ.S. (2015) Antitcoagulant and antiplatelet activities of scolymoside. BMB Reports, 48, 577–582.
42.
KuS.K., BaeJ.S. (2015) Baicalin, baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo. BMB Reports, 48, 519–524.
43.
BaeJ.S., LeeW., NamJ.O., KimJ.E., KimS.W., KimI.S. (2014) Transforming Growth Factor beta-induced Protein Promotes Severe Vascular Inflammatory Responses. American Journal of Respiratory and Critical Care Medicine, 189, 779–786.
RittirschD., Huber-LangM.S., FlierlM.A., WardP.A. (2009) Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocol, 4, 31–36.
46.
MenschikowskiM., HagelgansA., HeyneB., HempelU., NeumeisterV., GoezP., JarossW., SiegertG. (2005) Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochimica et Biophysica Acta, 1733, 157–171.
47.
BaeJ.S., RezaieA.R. (2010) Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thrombosis Research, 125, e9–e15.
48.
ShimoyamaY., SakamotoR., AkaboshiT., TanakaM., OhtsukiK. (2001) Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro. Biological & Pharmaceutical Bulletin, 24, 1004–1008.
49.
DunnettC.W. (1964) New tables for multiple comparisons with a control. Biometrics, 20, 482–491.
